Bayer has signed a partnership with Absolute's biologicals arm INERA to expand biological crop nutrition across India, the companies announced in a release carried by The Economic Times.

The agreement links Bayer, one of the country's largest input suppliers, with INERA, the crop-nutrition division of agri-tech firm Absolute. Biologicals — microbial and bio-based nutrition and crop-protection products — sit at the center of the deal.

What does the deal cover?

The partnership targets wider distribution of INERA's biological crop nutrition portfolio through Bayer's commercial channels in India. It pairs a global input maker's field network with a domestic biologicals developer.

For growers, the practical question is cost and performance. Biological nutrition products typically compete with conventional fertilizer programs on price per acre and yield response, and adoption depends on demonstrable returns rather than category labels.

Why India, and why biologicals now?

Indian farm input markets face sustained pressure on fertilizer subsidy budgets and rising urea and nutrient costs. Biologicals offer suppliers a growth segment and offer policymakers a lever to moderate nutrient demand.

Absolute, the parent of INERA, has positioned itself as an agri-tech and biologicals platform serving Indian growers. Bayer brings distribution scale and an established farmer base.

The companies did not disclose financial terms, acreage targets or launch timelines in the announcement.

What to watch

Key metrics for judging the partnership will be product registration status, states covered in the first rollout, and any yield or input-cost data from replicated field trials rather than condition claims.

Bayer has previously pursued biologicals partnerships in other markets as it diversifies beyond synthetic chemistry. The India agreement extends that strategy into one of the world's largest crop-input markets by volume.

The release gives no harvest-season results tied to the products; any performance claims at this stage are forward-looking.

Watch for first distribution figures, trial data and state-level launches as the program moves from announcement to shelf.